Bindra Jas, Chopra Ishveen, Hayes Kyle, Niewoehner John, Panaccio Mary, Elliott Sheila, Trawick Bobby, Wan George J
Falcon Research Group, North Potomac, MD, USA.
Manticore Consultancy, Bethesda, MD, USA.
Adv Ther. 2025 Jul;42(7):3386-3399. doi: 10.1007/s12325-025-03232-5. Epub 2025 May 22.
Acthar Gel Single-Dose Pre-filled SelfJect™ Injector ("Acthar Gel via SelfJect") is approved by the US Food and Drug Administration for appropriate patients with chronic and acute inflammatory and autoimmune conditions. It has fewer steps than a multi-dose vial. This survey assessed patients' perceptions of their experience with this device, including their satisfaction, confidence, convenience, and ease of use, as well as persistence and compliance.
Real-World Insights on Patient Satisfaction and Experience with Acthar Gel via SelfJect (RISE™) gathered responses via a non-interventional, observational, cross-sectional online survey with a pre-specified protocol (November 2024-January 2025). Eligible participants were aged ≥18 years, had a diagnosis of an indication of Acthar Gel based on the prescribing information, and had used Acthar Gel via SelfJect for ≥6 self-injections during the survey.
Fifty-four participants completed the survey (mean age 55.4 years, 76% women). Thirty-three percent (18/54) had chronic or recurring ocular inflammatory disease, and 26% (14/54) had rheumatoid arthritis. Thirty-nine percent (21/54) reported dexterity or visual problems, and 39% (21/54) had prior experience with Acthar Gel multi-dose vial. On average, administering Acthar Gel via SelfJect took 3.4 min. Overall, 91% (49/54) of participants reported that they were satisfied or very satisfied with Acthar Gel via SelfJect; 89% (48/54) felt very or extremely confident injecting with Acthar Gel via SelfJect; and 91% (49/54) found it to be convenient or very convenient. Seventy-six percent (41/54) felt that it was very or extremely easy to self-inject with this device. Eighty-seven percent (47/54) perceived that they were likely or very likely to maintain persistence and compliance with this device.
Survey participants reported a favorable experience with Acthar Gel via SelfJect, with a high level of satisfaction, confidence, convenience, and ease of use. Participants reported perceptions of anticipated positive persistence and compliance with this device, which may correlate with the possibility of improved continuity of care.
Acthar Gel单剂量预填充自动注射器（“通过SelfJect使用Acthar Gel”）已获美国食品药品监督管理局批准，适用于患有慢性和急性炎症及自身免疫性疾病的合适患者。它比多剂量药瓶的步骤更少。本次调查评估了患者对该设备使用体验的看法，包括他们的满意度、信心、便利性、易用性，以及持续性和依从性。
关于通过SelfJect使用Acthar Gel的患者满意度和体验的真实世界洞察（RISE™）通过一项具有预先指定方案的非干预性、观察性横断面在线调查收集反馈（2024年11月至2025年1月）。符合条件的参与者年龄≥18岁，根据处方信息诊断患有Acthar Gel适用的疾病，并且在调查期间通过SelfJect使用Acthar Gel进行了≥6次自我注射。
54名参与者完成了调查（平均年龄55.4岁，76%为女性）。33%（18/54）患有慢性或复发性眼部炎症疾病，26%（14/54）患有类风湿性关节炎。39%（21/54）报告存在灵活性或视力问题，39%（21/54）曾有过使用Acthar Gel多剂量药瓶的经历。平均而言，通过SelfJect注射Acthar Gel需要3.4分钟。总体而言，91%（49/54）的参与者报告他们对通过SelfJect使用Acthar Gel感到满意或非常满意；89%（48/54）对通过SelfJect注射Acthar Gel感到非常有信心或极其有信心；91%（49/54）认为它方便或非常方便。76%（41/54）觉得使用该设备进行自我注射非常容易或极其容易。87%（47/54）认为他们很可能或非常可能持续使用并依从该设备。
调查参与者报告了通过SelfJect使用Acthar Gel的良好体验，满意度、信心、便利性和易用性都很高。参与者报告了对该设备预期的积极持续性和依从性的看法，这可能与改善护理连续性的可能性相关。
